90729-86-5

Upstream product

• 141-82-2 malonic acid 
• 704-13-2 5-formyl-2-nitrophenol 
• 14755-02-3 3-hydroxycinnamic acid 
• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 14755-02-3 3-hydroxy-trans-cinnamic acid 

Downstream Products

• 619-14-7 3-hydroxy-4-nitro-benzoic acid 
• 1224873-10-2 (E)-N-(3-chlorophenyl)-3-(4-amino-3-hydroxyphenyl)-prop-2-enamide 
• 1224873-09-9 (E)-N-(3-chlorophenyl)-3-(3-hydroxy-4-nitrophenyl)-prop-2-enamide 

Relevant academic research and scientific papers

Nitration of cinnamic acids using cerium (IV) ammonium nitrate immobilized on silica

Treatment of cinnamic acids with cerium (IV) ammonium nitrate supported on silica (CAN/SiO2) was used to synthesize nitro derivative and ipso substitution products. The position of the substituents defines the type and the yields of the product

Bicyclic cyclohexylamines and their use as nmda receptor antagonists

Described are heterocycle-substituted cyclohexylamines of formula (I), and their pharmaceutically acceptable salts thereof. The compounds of formula (I) are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders suc

IL-8 RECEPTOR ANTAGONISTS

The present invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease states mediated by the chemokine Interleukin-8 (IL-8).

IL-8 RECEPTOR ANTAGONISTS

This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

IL-8 RECEPTOR ANTAGONISTS

This invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease scates mediated by the chemokine, Interleukin-8 (IL-8). In particular, this invention relates to the novel compounds of Formula (Ia) and their use in treating chemokine mediated diseases wherein the chemokine binds to an IL-8 a or b receptor. Compounds of Formula (Ia) are represented by the structure: STR1 wherein interalia, X is oxygen or sulfur;Rb is NR 6 R. sub.7, alkcyl, aryl, arylC 1-4 alkyl, aryl C 2-4 alkenyl, heteroaryl, heteroarylC 1-4 alkyl, heteroarylC 2-4 alkenyl, heterocyclic or heterocyclic C 1-4 alkyl, or a heterocyclic C 2-4 alkenyl moiety, camphor, all of which may be optionally substituted; R 1 is independently selected from hydrogen; halogen; nitro; cyano; C 1-10 alkyl; halosubstituted C 1-10 alkyl; C 2-10 alkoxy; halosubstituted C 1-10 alkoxy; azide; (CR. sub.8 R 8)q S(O) t R 4 ; hydroxy; hydroxy substituted C 1-4 alkyl; aryl; aryl C 1-4 alkyl; aryl C 2-10 alkenyl; aryloxy; aryl C 1-4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl C 2-10 alkenyl; heteroaryl C 1-4 alkyloxy; heterocyclic; heterocyclic C 1-4 alkyl; heterocyclicC 1-4 alkyloxy; heterocyclic C 2-10 alkenyl; q is 0 or an integer having a value of 1 to 10; n is an integer having a value of 1 to 3;m is an integer having a value of 1 to 3; Y is hydrogen; halogen; nitro; cyano; halosubstituted C 1-10 alkyl; C 1-10 alkyl; C 2-10 alkenyl C. sub.1-10 alkoxy; halosubstituted C 1-10 alkoxy; azide; (CR 8 R. sub.8)qS(O) t R 4, (CR 8 R 8)qOR 4 ; hydorxy; hydroxy substituted C. sub.1-4 alkyl; aryl; aryl C 1-4 alkyl; aryloxy; arylC. sub.1-4 alkyloxy; aryl C 2-10 alkenyl; heteroaryl; heteroarylalkyl; heteroaryl C 1-4 alkyloxy; heteroaryl C 2-10 alkenyl; heterocyclic, heterocyclic C 1-4 alkyl; heterocyclicC 2-10 alkenyl;or a pharmaceutically acceptable salt thereof.